Skip to main content
Erschienen in: Digestive Diseases and Sciences 10/2022

13.01.2022 | Original Article

Metformin Use Is Inversely Associated with Prevalent, but Not Incident Colorectal Adenomas

verfasst von: Anna Krigel, Snow Trinh T. Nguyen, Nawar Talukder, Ching-Ho Huang, Carlos Buitrago, Gabriel Karkenny, Benjamin Lebwohl, Julian A. Abrams, James L. Araujo

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Chemoprevention for colorectal neoplasia has attracted growing interest, with multiple medications investigated. Metformin may decrease the overall incidence of cancer in patients with diabetes and may decrease the incidence of colorectal cancer.

Aims

We aimed to determine the impact of metformin use on the behavior of colorectal adenomas in a US veteran population.

Methods

All patients with at least two high-quality colonoscopies between January 1997 and December 2013 at Veterans Affairs New York Harbor Healthcare System were identified. Outpatient prescription records were used to determine metformin exposure, and colonoscopy findings were recorded. Multivariable logistic regression was used to determine factors associated with adenoma detection on baseline and interval colonoscopy.

Results

In total, 1869 patients with two successive colonoscopies (median 4.5 years) were included. Four hundred and sixty patients had metformin exposure prior to baseline and/or interval colonoscopy. Overall adenoma detection rate was 59.7% at baseline and 45.9% at interval colonoscopy. On multivariable analysis, metformin use was associated with decreased adenoma prevalence at baseline (OR 0.68; 95% CI 0.51–0.92; p = 0.015). Metformin did not impact adenoma incidence at interval colonoscopy whether prescribed before baseline (OR 1.26; 95% CI 0.60–2.67), after baseline (OR 1.25; 95% CI 0.91–1.72), or before and after baseline (OR 1.14; 95% CI 0.82–1.58).

Conclusions

In this retrospective analysis of an average-risk cohort, metformin use was associated with a decreased prevalence of colorectal adenomas at baseline colonoscopy. This inverse association did not persist on interval colonoscopy. Prospective studies are needed to evaluate potential chemoprotective effects of metformin over time.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.CrossRef Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.CrossRef
2.
Zurück zum Zitat Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977–1981.CrossRef Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977–1981.CrossRef
3.
Zurück zum Zitat Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687–696.CrossRef Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687–696.CrossRef
4.
Zurück zum Zitat Liang PS, Shaukat A, Crockett SD. AGA clinical practice update on chemoprevention for colorectal neoplasia: expert review. Clin Gastroenterol Hepatol 2021;19:1327–1336.CrossRef Liang PS, Shaukat A, Crockett SD. AGA clinical practice update on chemoprevention for colorectal neoplasia: expert review. Clin Gastroenterol Hepatol 2021;19:1327–1336.CrossRef
5.
Zurück zum Zitat Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–1305.CrossRef Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–1305.CrossRef
6.
Zurück zum Zitat Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 2014;7:867–885.CrossRef Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 2014;7:867–885.CrossRef
7.
Zurück zum Zitat Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620–1625.CrossRef Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620–1625.CrossRef
8.
Zurück zum Zitat He XK, Su TT, Si JM, et al. Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: a meta-analysis. Medicine (Baltimore) 2016;95:e2749.CrossRef He XK, Su TT, Si JM, et al. Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: a meta-analysis. Medicine (Baltimore) 2016;95:e2749.CrossRef
9.
Zurück zum Zitat Liu F, Yan L, Wang Z, et al. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Oncotarget 2017;8:16017–16026.CrossRef Liu F, Yan L, Wang Z, et al. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Oncotarget 2017;8:16017–16026.CrossRef
10.
Zurück zum Zitat Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 2016;17:475–483.CrossRef Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 2016;17:475–483.CrossRef
11.
Zurück zum Zitat Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010;3:1077–1083.CrossRef Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010;3:1077–1083.CrossRef
12.
Zurück zum Zitat Hou YC, Hu Q, Huang J, et al. Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: a meta-analysis. Oncotarget 2017;8:8843–8853.CrossRef Hou YC, Hu Q, Huang J, et al. Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: a meta-analysis. Oncotarget 2017;8:8843–8853.CrossRef
13.
Zurück zum Zitat Jung YS, Park CH, Eun CS, et al. Metformin use and the risk of colorectal adenoma: a systematic review and meta-analysis. J Gastroenterol Hepatol 2017;32:957–965.CrossRef Jung YS, Park CH, Eun CS, et al. Metformin use and the risk of colorectal adenoma: a systematic review and meta-analysis. J Gastroenterol Hepatol 2017;32:957–965.CrossRef
14.
Zurück zum Zitat Mansourian M, Karimi R, Vaseghi G. Different effects of metformin and insulin on primary and secondary chemoprevention of colorectal adenoma in diabetes type 2: traditional and Bayesian meta-analysis. EXCLI J 2018;17:45–56.PubMedPubMedCentral Mansourian M, Karimi R, Vaseghi G. Different effects of metformin and insulin on primary and secondary chemoprevention of colorectal adenoma in diabetes type 2: traditional and Bayesian meta-analysis. EXCLI J 2018;17:45–56.PubMedPubMedCentral
15.
Zurück zum Zitat American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 2019;42:S13–S28.CrossRef American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 2019;42:S13–S28.CrossRef
16.
Zurück zum Zitat Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665–2673.CrossRef Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665–2673.CrossRef
17.
Zurück zum Zitat Cho YH, Ko BM, Kim SH, et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest Res 2014;12:139–145.CrossRef Cho YH, Ko BM, Kim SH, et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest Res 2014;12:139–145.CrossRef
18.
Zurück zum Zitat Kanadiya MK, Gohel TD, Sanaka MR, et al. Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. J Diabetes Complicat 2013;27:463–466.CrossRef Kanadiya MK, Gohel TD, Sanaka MR, et al. Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. J Diabetes Complicat 2013;27:463–466.CrossRef
19.
Zurück zum Zitat Chung YW, Han DS, Park KH, et al. Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum 2008;51:593–597.CrossRef Chung YW, Han DS, Park KH, et al. Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum 2008;51:593–597.CrossRef
20.
Zurück zum Zitat Eddi R, Karki A, Shah A, et al. Association of type 2 diabetes and colon adenomas. J Gastrointest Cancer 2012;43:87–92.CrossRef Eddi R, Karki A, Shah A, et al. Association of type 2 diabetes and colon adenomas. J Gastrointest Cancer 2012;43:87–92.CrossRef
21.
Zurück zum Zitat Wong P, Weiner MG, Hwang WT, et al. Insulin therapy and colorectal adenomas in patients with diabetes mellitus. Cancer Epidemiol Biomark Prev 2012;21:1833–1840.CrossRef Wong P, Weiner MG, Hwang WT, et al. Insulin therapy and colorectal adenomas in patients with diabetes mellitus. Cancer Epidemiol Biomark Prev 2012;21:1833–1840.CrossRef
22.
Zurück zum Zitat Jain D, Chhoda A, Uribe J. Effect of insulin and metformin combination treatment on colon adenoma and advanced adenoma among DM II. J Gastrointest Cancer 2016;47:404–408.CrossRef Jain D, Chhoda A, Uribe J. Effect of insulin and metformin combination treatment on colon adenoma and advanced adenoma among DM II. J Gastrointest Cancer 2016;47:404–408.CrossRef
23.
Zurück zum Zitat Kim YH, Noh R, Cho SY, et al. Inhibitory effect of metformin therapy on the incidence of colorectal advanced adenomas in patients with diabetes. Intest Res 2015;13:145–152.CrossRef Kim YH, Noh R, Cho SY, et al. Inhibitory effect of metformin therapy on the incidence of colorectal advanced adenomas in patients with diabetes. Intest Res 2015;13:145–152.CrossRef
24.
Zurück zum Zitat Han MS, Lee HJ, Park SJ, et al. The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. Int J Colorectal Dis 2017;32:1223–1226.CrossRef Han MS, Lee HJ, Park SJ, et al. The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. Int J Colorectal Dis 2017;32:1223–1226.CrossRef
25.
Zurück zum Zitat Marks AR, Pietrofesa RA, Jensen CD, et al. Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. Cancer Epidemiol Biomark Prev 2015;24:1692–1698.CrossRef Marks AR, Pietrofesa RA, Jensen CD, et al. Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. Cancer Epidemiol Biomark Prev 2015;24:1692–1698.CrossRef
26.
Zurück zum Zitat Shi X, Yang Z, Wu Q, et al. Colorectal adenoma recurrence rates among post-polypectomy patients in the placebo-controlled groups of randomized clinical trials: a meta-analysis. Oncotarget 2017;8:62371–62381.CrossRef Shi X, Yang Z, Wu Q, et al. Colorectal adenoma recurrence rates among post-polypectomy patients in the placebo-controlled groups of randomized clinical trials: a meta-analysis. Oncotarget 2017;8:62371–62381.CrossRef
28.
Zurück zum Zitat El-Halabi MM, Rex DK, Saito A, et al. Defining adenoma detection rate benchmarks in average-risk male veterans. Gastrointest Endosc 2019;89:137–143.CrossRef El-Halabi MM, Rex DK, Saito A, et al. Defining adenoma detection rate benchmarks in average-risk male veterans. Gastrointest Endosc 2019;89:137–143.CrossRef
29.
Zurück zum Zitat Kahi CJ, Ballard D, Shah AS, et al. Impact of a quarterly report card on colonoscopy quality measures. Gastrointest Endosc 2013;77:925–931.CrossRef Kahi CJ, Ballard D, Shah AS, et al. Impact of a quarterly report card on colonoscopy quality measures. Gastrointest Endosc 2013;77:925–931.CrossRef
30.
Zurück zum Zitat Rastogi A, Bansal A, Rao DS, et al. Higher adenoma detection rates with cap-assisted colonoscopy: a randomised controlled trial. Gut 2012;61:402–408.CrossRef Rastogi A, Bansal A, Rao DS, et al. Higher adenoma detection rates with cap-assisted colonoscopy: a randomised controlled trial. Gut 2012;61:402–408.CrossRef
31.
Zurück zum Zitat Rex DK, Ponugoti PL. Calculating the adenoma detection rate in screening colonoscopies only: is it necessary? Can it be gamed? Endoscopy 2017;49:1069–1074.CrossRef Rex DK, Ponugoti PL. Calculating the adenoma detection rate in screening colonoscopies only: is it necessary? Can it be gamed? Endoscopy 2017;49:1069–1074.CrossRef
32.
Zurück zum Zitat Baron JA, Barry EL, Mott LA, et al. A trial of calcium and vitamin D for the prevention of colorectal adenomas. N Engl J Med 2015;373:1519–1530.CrossRef Baron JA, Barry EL, Mott LA, et al. A trial of calcium and vitamin D for the prevention of colorectal adenomas. N Engl J Med 2015;373:1519–1530.CrossRef
33.
Zurück zum Zitat Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342:1149–1155.CrossRef Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342:1149–1155.CrossRef
Metadaten
Titel
Metformin Use Is Inversely Associated with Prevalent, but Not Incident Colorectal Adenomas
verfasst von
Anna Krigel
Snow Trinh T. Nguyen
Nawar Talukder
Ching-Ho Huang
Carlos Buitrago
Gabriel Karkenny
Benjamin Lebwohl
Julian A. Abrams
James L. Araujo
Publikationsdatum
13.01.2022
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 10/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07336-0

Weitere Artikel der Ausgabe 10/2022

Digestive Diseases and Sciences 10/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.